^
Association details:
| Biomarker: | ERBB3 overexpression |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | patritumab deruxtecan (U3-1402) (Topoisomerase I inhibitor, HER3-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in breast cancer patients: Phase 1 dose escalation study.
Excerpt:
HER3 IHC has been evaluated in 294 breast cancer pts, 87 (30%) showed high levels of HER3 expression....In a preliminary analysis of 21 pts, U3-1402 exhibits antitumor activity in previously treated HER3 expressing MBC pts and treatment is associated with a manageable safety profile.
Trial ID:
